The ZUMA-24 study showed outpatient axicabtagene ciloleucel (axi-cel) for DLBCL reduced hospitalization and improved safety profiles. CAR T-cell therapy for DLBCL shows promise in outpatient settings, ...
Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy combination improved outcomes for patients with metastatic clear-cell ...
In light of new data at ESMO, researchers debated whether HER2-targeted tyrosine kinase inhibitors or antibody-drug conjugates might be better as initial treatment.
Phase 2 study of pembrolizumab (pembro) plus plinabulin (plin) and docetaxel (doc) for patients (pts) with metastatic NSCLC after progression on first-line immune checkpoint inhibitor alone or ...
Eftilagimod alpha (efti), an antigen-presenting cell (APC) activator, may overcome PD-1/PD-L1 inhibitor primary resistance. This phase II study investigated efti plus pembrolizumab treatment in ...
I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.
Aug 15 (Reuters) - In the latest setback for Pfizer's (PFE.N), opens new tab sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal in a late-stage trial for patients ...
A multi-institutional study led by researchers at the University of Alabama at Birmingham and the University of North Carolina at Chapel Hill has revealed a previously underappreciated mechanism by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback